286 related articles for article (PubMed ID: 11080200)
21. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups.
Berglund BA; Boring DL; Wilken GH; Makriyannis A; Howlett AC; Lin S
Prostaglandins Leukot Essent Fatty Acids; 1998 Aug; 59(2):111-8. PubMed ID: 9774174
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
23. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation.
Selley DE; Rorrer WK; Breivogel CS; Zimmer AM; Zimmer A; Martin BR; Sim-Selley LJ
J Neurochem; 2001 May; 77(4):1048-57. PubMed ID: 11359870
[TBL] [Abstract][Full Text] [Related]
24. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
25. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
26. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
27. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain.
Breivogel CS; Childers SR; Deadwyler SA; Hampson RE; Vogt LJ; Sim-Selley LJ
J Neurochem; 1999 Dec; 73(6):2447-59. PubMed ID: 10582605
[TBL] [Abstract][Full Text] [Related]
28. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
29. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids.
Breivogel CS; Walker JM; Huang SM; Roy MB; Childers SR
Neuropharmacology; 2004 Jul; 47(1):81-91. PubMed ID: 15165836
[TBL] [Abstract][Full Text] [Related]
30. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
Hampson AJ; Bornheim LM; Scanziani M; Yost CS; Gray AT; Hansen BM; Leonoudakis DJ; Bickler PE
J Neurochem; 1998 Feb; 70(2):671-6. PubMed ID: 9453561
[TBL] [Abstract][Full Text] [Related]
31. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.
Cravatt BF; Demarest K; Patricelli MP; Bracey MH; Giang DK; Martin BR; Lichtman AH
Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9371-6. PubMed ID: 11470906
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain.
Hillard CJ; Wilkison DM; Edgemond WS; Campbell WB
Biochim Biophys Acta; 1995 Aug; 1257(3):249-56. PubMed ID: 7647100
[TBL] [Abstract][Full Text] [Related]
33. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis.
Berrendero F; Sánchez A; Cabranes A; Puerta C; Ramos JA; García-Merino A; Fernández-Ruiz J
Synapse; 2001 Sep; 41(3):195-202. PubMed ID: 11391780
[TBL] [Abstract][Full Text] [Related]
34. The orphan receptor GPR55 is a novel cannabinoid receptor.
Ryberg E; Larsson N; Sjögren S; Hjorth S; Hermansson NO; Leonova J; Elebring T; Nilsson K; Drmota T; Greasley PJ
Br J Pharmacol; 2007 Dec; 152(7):1092-101. PubMed ID: 17876302
[TBL] [Abstract][Full Text] [Related]
35. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and behavioral evaluation of alkylated anandamide analogs.
Adams IB; Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
Life Sci; 1995; 56(23-24):2041-8. PubMed ID: 7776830
[TBL] [Abstract][Full Text] [Related]
37. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
38. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
39. The neurobiology of cannabinoid transmission: from anandamide signaling to higher cerebral functions and disease.
Navarro M; Rodríguez de Fonseca F
Neurobiol Dis; 1998 Dec; 5(6 Pt B):379-85. PubMed ID: 9974172
[No Abstract] [Full Text] [Related]
40. Activation of G-proteins in brain by endogenous and exogenous cannabinoids.
Childers SR
AAPS J; 2006 Mar; 8(1):E112-7. PubMed ID: 16584117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
